Hospital
Georgetown Memorial Hospital
Georgetown Memorial Hospital was paid $27.63M by Medicaid between Jan 2018 and Dec 2024, across 316 billing codes. Its largest line is 36415, Collection of venous blood by venipuncture — 18% of everything it billed.
33Billing provider infoGEORGETOWN MEMORIAL HOSPITAL
GEORGETOWN, SC 29440
GEORGETOWN, SC 29440
33aNPI1982604021assigned 07/29/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$27.63M
24GClaims781,520
24DCodes billed316
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in South Carolina
Rank by total paid#12 of 115
Median peer was paid$2.47M
This provider vs. median11×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official WARD, ELIZABETH controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 108,680 | $3.34M | |
| 2019 | 130,626 | $3.55M | |
| 2020 | 99,572 | $3.18M | |
| 2021 | 103,298 | $3.15M | |
| 2022 | 115,330 | $4.48M | |
| 2023 | 128,207 | $6.62M | |
| 2024incomplete | 95,807 | $3.31M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 36415 | Collection of venous blood by venipuncture | 18% | 36,672 | 29,560 | $5.04M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 8.7% | 51,490 | 12,962 | $2.39M |
| 80053 | Comprehensive metabolic panel | 6.6% | 32,146 | 26,689 | $1.83M |
| 96375 | Therapeutic injection; each additional sequential IV push | 5.9% | 11,280 | 7,190 | $1.64M |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 5.3% | 8,222 | 6,579 | $1.46M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 4.9% | 34,857 | 33,142 | $1.36M |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 4.0% | 4,945 | 4,418 | $1.10M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 3.6% | 26,113 | 24,650 | $995K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.6% | 11,606 | 10,938 | $715K |
| 87070 | 2.4% | 6,750 | 6,443 | $652K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.3% | 6,618 | 3,394 | $642K |
| 81025 | 2.2% | 6,730 | 6,310 | $607K |
304 more codes
| 87081 | 1.8% | 3,274 | $493K | |
| 96367 | 1.6% | 2,028 | $430K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.1% | 8,685 | $315K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.0% | 5,339 | $277K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 8,211 | $263K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,363 | $252K |
| 99285 | Emergency room visit (most serious) | <1% | 9,247 | $248K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 7,187 | $245K |
| 87400 | <1% | 3,501 | $243K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 14,171 | $235K |
| 96402 | <1% | 265 | $227K | |
| 87481 | <1% | 810 | $211K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 8,284 | $196K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 7,098 | $184K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 6,014 | $184K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 6,960 | $174K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 4,181 | $165K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 7,248 | $160K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 9,555 | $159K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 4,213 | $151K |
| 96523 | <1% | 2,022 | $144K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 15,211 | $142K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 2,653 | $141K |
| 81003 | <1% | 17,912 | $130K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 925 | $130K |
| 74018 | <1% | 1,634 | $130K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,091 | $124K |
| 97035 | <1% | 2,013 | $118K | |
| 80081 | <1% | 1,070 | $111K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 8,831 | $107K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,142 | $106K |
| 73562 | <1% | 1,886 | $105K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,672 | $101K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 488 | $94K |
| J3490 | Unclassified drugs | <1% | 1,366 | $91K |
| 73630 | <1% | 1,675 | $82K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 2,243 | $81K |
| 73610 | <1% | 1,239 | $78K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 33,039 | $77K |
| 71045 | Radiologic examination, chest; single view | <1% | 6,421 | $75K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 3,639 | $71K |
| 97161 | <1% | 4,599 | $71K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 1,748 | $69K |
| 72110 | <1% | 1,210 | $69K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,745 | $69K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 9,457 | $67K |
| 87653 | <1% | 1,590 | $64K | |
| 73030 | <1% | 1,136 | $63K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 205 | $58K |
| 86850 | <1% | 1,861 | $50K | |
| 87077 | <1% | 3,008 | $49K | |
| 97014 | <1% | 556 | $48K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 10,733 | $47K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 645 | $45K |
| A4649 | Surgical supply; miscellaneous | <1% | 101 | $44K |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 65 | $43K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 6,026 | $42K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 8,895 | $42K |
| 93971 | <1% | 263 | $41K | |
| 82565 | <1% | 505 | $41K | |
| 73130 | <1% | 730 | $40K | |
| 82947 | <1% | 2,310 | $39K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 365 | $39K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 12,252 | $30K |
| 87807 | <1% | 3,136 | $29K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,071 | $28K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,538 | $27K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 3,401 | $27K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 210 | $27K |
| 72050 | <1% | 323 | $27K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 695 | $26K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,966 | $26K |
| 36416 | <1% | 305 | $24K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 245 | $24K |
| J2704 | Injection, propofol, 10 mg | <1% | 4,688 | $23K |
| 86592 | <1% | 1,447 | $23K | |
| 96376 | <1% | 1,957 | $22K | |
| 76641 | <1% | 314 | $22K | |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 42 | $20K |
| 97162 | <1% | 1,200 | $20K | |
| 84702 | <1% | 2,155 | $18K | |
| 82105 | <1% | 988 | $18K | |
| 85027 | <1% | 7,663 | $18K | |
| 0002A | <1% | 507 | $17K | |
| 59025 | Fetal non-stress test | <1% | 109 | $17K |
| 73110 | <1% | 394 | $17K | |
| 97116 | <1% | 1,952 | $16K | |
| 73502 | <1% | 353 | $16K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 273 | $16K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 534 | $15K |
| 86704 | <1% | 110 | $15K | |
| 0001A | <1% | 565 | $13K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 124 | $13K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 3,947 | $13K |
| 82607 | <1% | 1,338 | $13K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 533 | $12K |
| 86140 | <1% | 2,134 | $12K | |
| 73140 | <1% | 126 | $12K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 134 | $12K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 803 | $11K |
| 80061 | Lipid panel | <1% | 5,374 | $11K |
| 82728 | <1% | 2,514 | $11K | |
| 84439 | <1% | 2,752 | $10K | |
| 87329 | <1% | 85 | $9K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,887 | $9K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,761 | $9K |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 138 | $8K |
| 85652 | <1% | 1,805 | $8K | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 128 | $8K |
| 97113 | <1% | 182 | $7K | |
| 99223 | Prolong inpt eval add15 m | <1% | 56 | $6K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,601 | $6K |
| 87210 | <1% | 991 | $6K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,531 | $6K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,532 | $6K |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 2,499 | $6K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 72 | $5K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 9,346 | $5K |
| A9270 | Non-covered item or service | <1% | 17,253 | $5K |
| 93017 | <1% | 194 | $5K | |
| 36592 | <1% | 4,224 | $5K | |
| 87150 | <1% | 101 | $5K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 507 | $5K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 439 | $4K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 518 | $4K |
| G0378 | Hospital observation service, per hour | <1% | 1,960 | $4K |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 3,751 | $4K |
| 0003A | <1% | 110 | $4K | |
| 0071A | <1% | 100 | $4K | |
| 71250 | <1% | 24 | $4K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 683 | $3K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 952 | $3K |
| 80074 | <1% | 54 | $3K | |
| 93880 | <1% | 26 | $3K | |
| 0072A | <1% | 80 | $3K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 20 | $3K |
| L4350 | Ankle control orthosis, stirrup style, rigid, includes any type interface (e.g., pneumatic, gel), prefabricated, off-the-shelf | <1% | 13 | $3K |
| 96415 | <1% | 1,230 | $3K | |
| 97165 | <1% | 165 | $3K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 141 | $3K |
| 87430 | <1% | 346 | $3K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,150 | $3K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 960 | $3K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 2,596 | $3K |
| 86900 | <1% | 2,366 | $2K | |
| 86803 | <1% | 806 | $2K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 683 | $2K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,725 | $2K |
| 85730 | <1% | 3,447 | $2K | |
| 92523 | <1% | 13 | $2K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 400 | $2K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 61 | $2K |
| 10060 | <1% | 85 | $2K | |
| A7003 | Administration set, with small volume nonfiltered pneumatic nebulizer, disposable | <1% | 31 | $2K |
| 83001 | <1% | 42 | $2K | |
| L3908 | Wrist hand orthosis, wrist extension control cock-up, non molded, prefabricated, off-the-shelf | <1% | 12 | $2K |
| 80076 | <1% | 114 | $2K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 467 | $2K |
| 82950 | <1% | 161 | $2K | |
| 85651 | <1% | 564 | $2K | |
| 82042 | <1% | 168 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,246 | $2K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,295 | $2K |
| 77066 | Tomosynthesis, mammo | <1% | 12 | $2K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 20 | $2K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 910 | $1K |
| 73080 | <1% | 34 | $1K | |
| 87186 | <1% | 3,726 | $1K | |
| 83735 | <1% | 8,039 | $1K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 721 | $1K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 25 | $1K |
| 72100 | <1% | 12 | $1K | |
| 81001 | <1% | 771 | $964.39 | |
| 85379 | <1% | 1,886 | $952.88 | |
| 82570 | <1% | 618 | $939.48 | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 227 | $929.05 |
| 93000 | <1% | 104 | $909.47 | |
| 84703 | <1% | 278 | $876.41 | |
| 83540 | <1% | 2,380 | $875.67 | |
| 85014 | <1% | 733 | $866.33 | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 26 | $840.37 |
| 84484 | <1% | 7,304 | $756.91 | |
| 85610 | <1% | 7,277 | $754.98 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,098 | $743.30 |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,161 | $731.76 |
| 82550 | <1% | 3,415 | $725.13 | |
| 73590 | <1% | 13 | $648.69 | |
| 84481 | <1% | 478 | $615.83 | |
| 87040 | <1% | 2,259 | $608.34 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 5,208 | $560.85 |
| 86317 | <1% | 87 | $523.33 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 32 | $520.55 |
| 97542 | <1% | 13 | $501.06 | |
| 82043 | <1% | 71 | $480.87 | |
| 87205 | <1% | 2,058 | $479.24 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 222 | $461.01 |
| 83880 | <1% | 1,908 | $443.15 | |
| 0012A | <1% | 13 | $441.63 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 214 | $439.09 |
| 94760 | <1% | 693 | $429.17 | |
| 83690 | <1% | 6,051 | $379.41 | |
| 0011A | <1% | 17 | $373.60 | |
| 74019 | <1% | 12 | $281.87 | |
| 82247 | <1% | 56 | $280.78 | |
| 20610 | <1% | 242 | $260.42 | |
| 87340 | <1% | 466 | $254.00 | |
| 83021 | <1% | 131 | $251.60 | |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | <1% | 104 | $237.25 |
| 82150 | <1% | 397 | $212.90 | |
| 83020 | <1% | 40 | $206.95 | |
| 87076 | <1% | 34 | $206.49 | |
| 82378 | <1% | 189 | $177.70 | |
| 97164 | <1% | 12 | $156.78 | |
| 82465 | <1% | 49 | $141.59 | |
| 74022 | <1% | 126 | $127.09 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 40 | $119.06 |
| 29581 | <1% | 303 | $109.85 | |
| 84550 | <1% | 26 | $100.83 | |
| 29505 | <1% | 27 | $97.01 | |
| 82805 | <1% | 53 | $93.74 | |
| 86762 | <1% | 263 | $73.14 | |
| 83655 | <1% | 14 | $51.34 | |
| 83605 | <1% | 3,315 | $43.86 | |
| 86901 | <1% | 2,371 | $41.57 | |
| 84100 | <1% | 861 | $34.33 | |
| 85018 | <1% | 762 | $28.79 | |
| 90715 | <1% | 168 | $28.68 | |
| 82784 | <1% | 240 | $25.18 | |
| 85007 | <1% | 68 | $17.75 | |
| 82746 | <1% | 698 | $17.22 | |
| 86787 | <1% | 213 | $16.94 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,130 | $14.87 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 448 | $13.94 |
| 87075 | <1% | 945 | $12.57 | |
| 83615 | <1% | 356 | $6.81 | |
| 84156 | <1% | 104 | $4.82 | |
| 96417 | 0% | 1,806 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 38 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 602 | $0.00 |
| 80164 | 0% | 16 | $0.00 | |
| 85045 | 0% | 513 | $0.00 | |
| 29125 | 0% | 12 | $0.00 | |
| 84145 | 0% | 864 | $0.00 | |
| 82248 | 0% | 55 | $0.00 | |
| 83525 | 0% | 206 | $0.00 | |
| 85046 | 0% | 149 | $0.00 | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | 0% | 33 | $0.00 |
| 36600 | 0% | 12 | $0.00 | |
| 86677 | 0% | 38 | $0.00 | |
| 62323 | 0% | 50 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 126 | $0.00 |
| 84165 | 0% | 13 | $0.00 | |
| 82785 | 0% | 52 | $0.00 | |
| 99152 | 0% | 106 | $0.00 | |
| J0897 | Injection, denosumab, 1 mg | 0% | 25 | $0.00 |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | 0% | 13 | $0.00 |
| 83721 | 0% | 19 | $0.00 | |
| 83718 | 0% | 48 | $0.00 | |
| 80143 | 0% | 26 | $0.00 | |
| 86705 | 0% | 55 | $0.00 | |
| 84146 | 0% | 24 | $0.00 | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | 0% | 16 | $0.00 |
| J9190 | Injection, fluorouracil, 500 mg | 0% | 41 | $0.00 |
| 77002 | 0% | 18 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 54 | $0.00 |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 0% | 36 | $0.00 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 16 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 21 | $0.00 |
| 86038 | 0% | 13 | $0.00 | |
| 82009 | 0% | 85 | $0.00 | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | 0% | 34 | $0.00 |
| 80179 | 0% | 25 | $0.00 | |
| J9271 | Injection, pembrolizumab, 1 mg | 0% | 34 | $0.00 |
| 96411 | 0% | 41 | $0.00 | |
| 80320 | 0% | 662 | $0.00 | |
| 83550 | 0% | 2,272 | $0.00 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 545 | $0.00 |
| 82553 | 0% | 547 | $0.00 | |
| 82077 | 0% | 759 | $0.00 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 71 | $0.00 |
| 88342 | 0% | 283 | $0.00 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 94 | $0.00 |
| 86300 | 0% | 333 | $0.00 | |
| 86304 | 0% | 14 | $0.00 | |
| 82677 | 0% | 70 | $0.00 | |
| 83520 | 0% | 71 | $0.00 | |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 39 | $0.00 |
| Q3014 | Telehealth originating site facility fee | 0% | 222 | $0.00 |
| 87147 | 0% | 569 | $0.00 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 91 | $0.00 |
| 84153 | 0% | 44 | $0.00 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 80 | $0.00 |
| J9045 | Injection, carboplatin, 50 mg | 0% | 135 | $0.00 |
| 86706 | 0% | 142 | $0.00 | |
| J2505 | Injection, pegfilgrastim, 6 mg | 0% | 16 | $0.00 |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 0% | 92 | $0.00 |
| 96368 | 0% | 51 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 80 | $0.00 |
| 87522 | Neg quan hep c or qual rna | 0% | 13 | $0.00 |
| 36591 | 0% | 287 | $0.00 | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 0% | 15 | $0.00 |
| 83002 | 0% | 24 | $0.00 | |
| J9267 | Injection, paclitaxel, 1 mg | 0% | 112 | $0.00 |
| J1439 | Injection, ferric carboxymaltose, 1 mg | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWARD, ELIZABETH (EVP & CFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.